Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Cybulla

Showing results (1-10 of 30) with videos related to

Pageof 3
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging|January 23, 2003
90Y-DOTATOC and nephrotoxicityAndreas Otte, Markus Cybulla, Stefan M Weiner
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research|April 16, 2002
Is (90)Y-DOTATOC treatment for neuroendocrine tumours safe?Markus Cybulla, Stefan M Weiner, Andreas Otte
Lancet (London, England)|March 29, 2002
Is radiation nephropathy caused by yttrium-90?Andreas Otte, Stefan M Weiner, Markus Cybulla
Frontiers in Immunology|January 29, 2026
A rapid method to reduce drug interferences for antibody measurements in pegunigalsidase alfa-treated patients with Fabry diseaseMalte Lenders, Elisa Rudolph, Michael Rudnicki, et al.
American Journal of Nephrology|November 1, 2008
Agalsidase alfa slows the decline in renal function in patients with Fabry diseaseSandro Feriozzi, Andreas Schwarting, Gere Sunder-Plassmann, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|November 30, 2024
Relevance of Neutralizing Antibodies for the Pharmacokinetics of Pegunigalsidase Alfa in Patients with Fabry DiseaseMalte Lenders, Elise Raphaela Menke, Michael Rudnicki, et al.
Clinical Journal of the American Society of Nephrology : CJASN|January 17, 2012
The effectiveness of long-term agalsidase alfa therapy in the treatment of Fabry nephropathySandro Feriozzi, Joan Torras, Markus Cybulla, et al.
Neuroendocrinology|October 13, 2004
When to look for Von Hippel-Lindau disease in gastroenteropancreatic neuroendocrine tumors?Hao Ling, Markus Cybulla, Oliver Schaefer, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|February 12, 2009
Kidney transplantation in patients with Fabry diseaseMarkus Cybulla, Kerstin Nanette Walter, Andreas Schwarting, et al.
Journal of Nephrology|October 2, 2012
Kidney transplantation and enzyme replacement therapy in patients with Fabry diseaseMarkus Cybulla, Christine Kurschat, Michael West, et al.
Pageof 3

Showing results (1-10 of 30) with videos related to

Sort By:
Pageof 3
European Journal of Nuclear Medicine and Molecular Imaging|January 23, 2003
90Y-DOTATOC and nephrotoxicityAndreas Otte, Markus Cybulla, Stefan M Weiner
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research|April 16, 2002
Is (90)Y-DOTATOC treatment for neuroendocrine tumours safe?Markus Cybulla, Stefan M Weiner, Andreas Otte
Lancet (London, England)|March 29, 2002
Is radiation nephropathy caused by yttrium-90?Andreas Otte, Stefan M Weiner, Markus Cybulla
Frontiers in Immunology|January 29, 2026
A rapid method to reduce drug interferences for antibody measurements in pegunigalsidase alfa-treated patients with Fabry diseaseMalte Lenders, Elisa Rudolph, Michael Rudnicki, et al.
American Journal of Nephrology|November 1, 2008
Agalsidase alfa slows the decline in renal function in patients with Fabry diseaseSandro Feriozzi, Andreas Schwarting, Gere Sunder-Plassmann, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|November 30, 2024
Relevance of Neutralizing Antibodies for the Pharmacokinetics of Pegunigalsidase Alfa in Patients with Fabry DiseaseMalte Lenders, Elise Raphaela Menke, Michael Rudnicki, et al.
Clinical Journal of the American Society of Nephrology : CJASN|January 17, 2012
The effectiveness of long-term agalsidase alfa therapy in the treatment of Fabry nephropathySandro Feriozzi, Joan Torras, Markus Cybulla, et al.
Neuroendocrinology|October 13, 2004
When to look for Von Hippel-Lindau disease in gastroenteropancreatic neuroendocrine tumors?Hao Ling, Markus Cybulla, Oliver Schaefer, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|February 12, 2009
Kidney transplantation in patients with Fabry diseaseMarkus Cybulla, Kerstin Nanette Walter, Andreas Schwarting, et al.
Journal of Nephrology|October 2, 2012
Kidney transplantation and enzyme replacement therapy in patients with Fabry diseaseMarkus Cybulla, Christine Kurschat, Michael West, et al.
Pageof 3